Drugs Policy in Developing Countries

Najmi Kanji is a research fellow in the Health Policy Unit at the London School of Hygiene & Tropical Medicine.Anita Hardon is a medical biologist in the Medical Anthropology Unit of the University of Amsterdam.Jan Willem Harnmeijer works in the Primary Health Care Unit at the Royal Tropical Institute in Amsterdam.Masuma Mamdani is an epidemiologist and research fellow at the London School of Hygiene & Tropical Medicine.Gill Walt is a senior lecturer and head of the Health Policy Unit at the London School of Hygiene & Tropical Medicine

• Tables and FiguresContributorsForeword and AcknowledgementsAcronyms and Abbreviations1. Early Initiatives in Essential Drugs Policy - Masuma Mamdani2. Formulating an Essential Drugs Policy: WHO's Role - Gill Walt and Jan Willem Harnmeijer3. Consumers versus Producers: Power Play Behind the Scenes - Anita Hardon4. Action at Country Level: The International and National Influences - Najmi Kanji5. What Has Been Achieved and Where are We Now? - Najmi Kanji and Anita Hardon6. New Horizons in the 1990s - Anita Hardon and Najmi KanjiAppendixIndex

'Anyone who wants to understand the limitations and constraints of developing and executing a global policy to improve health in developing countries will find this book essential reading.'Calvin M. Kunin, M.D., Department of Internal Medicine, Ohio State University'This book comes as a welcome reminder of the many efforts to develop policies for a more rational use of medecines. It provides a clear outline of some of the possible strategies to achieve change.'Andrew Chetley, author of A Healthy Business: World Health and the Pharmaceutical Industry'The WHO has succeeded in making "essential drugs" a respected concept. This book documents this crucial step in the improvement of the supply of medicines for people in the South.'Sjaak van der Geest, University of Amsterdam